期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 28, 期 30, 页码 4616-4620出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.29.6038
关键词
-
类别
资金
- Xcovery
- National Basic Research Program of China [2010CB912102]
- National Natural Science Foundation of China [30623003, 30740084, 30871284]
- Chinese Academy of Sciences [2008KIP101, KSCX1-YW-22]
- Science and Technology Commission of Shanghai Municipality [08PJ14105, 09JC1416300]
- National Cancer Institute [R01 CA121210]
- Specialized Program of Research Excellence in Lung Cancer [CA90949]
- Vanderbilt-Ingram Cancer Center [CA68485]
Purpose To determine the proportion of lung adenocarcinomas from East Asian never-smokers who harbor known oncogenic driver mutations. Patients and Methods In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1. Results Forty-one tumors harbored EGFR mutations, three harbored EML4-ALK fusions, two harbored HER2 insertions, and one harbored a KRAS mutation. All mutations were mutually exclusive. Thus, 90% (47 of 52; 95% CI, 0.7896 to 0.9625) of lung adenocarcinomas from never-smokers were found to harbor well-known oncogenic mutations in just four genes. No BRAF, NRAS, HRAS, or LKB1 mutations were detected, while 15 had TP53 mutations. Four tumors contained PIK3CA mutations, always together with EGFR mutations. Conclusion To our knowledge, this study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers. Since drugs are now available that target mutant EGFR, HER2, and ALK, respectively, this result indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据